BridgeBio Pharma (BBIO) FCF Payout Ratio (2019)

BridgeBio Pharma (BBIO) reported FCF Payout Ratio of 0.69 for Q4 2019, down 4040.0% sequentially from 0.02 in Q1 2019.

BridgeBio Pharma (BBIO) FCF Payout Ratio (2019) Analysis & Trends

BridgeBio Pharma (BBIO) has 1 years of FCF Payout Ratio data on file, last reported at 0.69 in Q4 2019.

For the quarter ending Q4 2019, FCF Payout Ratio changed N/A year-over-year to 0.69; the trailing twelve-month figure through Dec 2019 stood at 0.21 (changed N/A YoY), and the FY2020 full-year result was 0.01, up 94.17% from the prior year.
FCF Payout Ratio slipped to 0.69 in Q4 2019, from 0.02 in the prior quarter.
In the past five years, FCF Payout Ratio ranged from a high of 0.02 in Q1 2019 to a low of 0.69 in Q4 2019.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Cover (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	0.12
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	BridgeBio Pharma	16.15 Bn	15.22 Bn	184.58 Mn	-

Historic Data

Download Data

Date	Value
Dec 31, 2019	-0.69
Mar 31, 2019	-0.02